Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid

Friedman,Marissa D.; Jeevan,Dhruve S.; Tobias,Michael; Murali,Raj; Jhanwar-Uniyal,Meena

doi:10.3892/or.2013.2625

Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid

Authors:
- Marissa D. Friedman
- Dhruve S. Jeevan
- Michael Tobias
- Raj Murali
- Meena Jhanwar-Uniyal
View Affiliations

Affiliations: Department of Neurosurgery, New York Medical College, Valhalla, NY 10595, USA
Published online on: July 18, 2013 https://doi.org/10.3892/or.2013.2625
Pages: 1645-1650

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM), the most aggressive primary brain tumor, portends a poor prognosis despite current treatment modalities. Recurrence of tumor growth is attributed to the presence of treatment-resistant cancer stem cells (CSCs). The targeting of these CSCs is therefore essential in the treatment of this disease. Mechanistic target of rapamycin (mTOR) forms two multiprotein complexes, mTORC1 and mTORC2, which regulate proliferation and migration, respectively. Aberrant function of mTOR has been shown to be present in GBM CSCs. All-trans retinoic acid (ATRA), a derivative of retinol, causes differentiation of CSCs as well as normal neural progenitor cells. The purpose of this investigation was to delineate the role of mTOR in CSC maintenance, and to establish the mechanism of targeting GBM CSCs using differentiating agents along with inhibitors of the mTOR pathways. The results demonstrated that ATRA caused differentiation of CSCs, as demonstrated by the loss of the stem cell marker Nestin. These observations were confirmed by western blotting, which demonstrated a time-dependent decrease in Nestin expression following ATRA treatment. This effect occurred despite combination with mTOR (rapamycin), PI3K (LY294002) and MEK1/2 (U0126) inhibitors. Expression of activated extracellular signal-regulated kinase 1/2 (pERK1/2) was enhanced following treatment with ATRA, independent of mTOR pathway inhibitors. Proliferation of CSCs, determined by neurosphere diameter, was decreased following treatment with ATRA alone and in combination with rapamycin. The motility of GBM cells was mitigated by treatment with ATRA, rapamycin and LY29002 alone. However, combination treatment augmented the inhibitory effect on migration suggesting synergism. These findings indicate that ATRA-induced differentiation is mediated via the ERK1/2 pathway, and underscores the significance of including differentiating agents along with inhibitors of mTOR pathways in the treatment of GBM.

View Figures

View References

1	Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, et al: Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer. 118:4228–4234. 2012. View Article : Google Scholar : PubMed/NCBI
2	Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, et al: Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13:355–364. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
4	Endersby R and Baker SJ: PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 27:5416–5430. 2008. View Article : Google Scholar : PubMed/NCBI
5	Holland EC, Hively WP, DePinho RA and Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12:3675–3685. 1998. View Article : Google Scholar
6	Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004. View Article : Google Scholar : PubMed/NCBI
7	Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med. 353:811–822. 2005. View Article : Google Scholar : PubMed/NCBI
8	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 39:193–206. 2002. View Article : Google Scholar : PubMed/NCBI
10	Jhanwar-Uniyal M, Albert L, McKenna E, Karsy M, Rajdev P, Braun A and Murali R: Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Adv Enzyme Regul. 51:164–170. 2011. View Article : Google Scholar : PubMed/NCBI
11	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
12	Jhanwar-Uniyal M, Jeevan D, Neil J, Shannon C, Albert L and Murali R: Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv Biol Regul. 53:202–210. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
14	Gan B, Sahin E, Jiang S, Sanchez-Aguilera A, Scott KL, Chin L, et al: mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA. 105:19384–19389. 2008. View Article : Google Scholar : PubMed/NCBI
15	Das A, Banik NL and Ray SK: Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol. 87:9–22. 2008. View Article : Google Scholar
16	Guan K, Chang H, Rolletschek A and Wobus AM: Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells. Cell Tissue Res. 305:171–176. 2001. View Article : Google Scholar : PubMed/NCBI
17	Das A, Banik NL and Ray SK: Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells. Neurochem Res. 34:87–101. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang R, Banik NL and Ray SK: Combination of all-trans retinoic acid and interferon-gamma upregulated p27^(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (pten-proficient) and U87MG (pten-deficient) cells. Cancer Chemother Pharmacol. 62:407–416. 2008.
19	Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL and Ray SK: Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol Immunother. 56:615–625. 2007.PubMed/NCBI
20	Defer GL, Adle-Biassette H, Ricolfi F, Martin L, Authier FJ, Chomienne C, et al: All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol. 34:169–177. 1997. View Article : Google Scholar
21	Clark MJ, Homer N, O’Connor BD, Chen Z, Eskin A, Lee H, et al: U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet. 6:e10008322010. View Article : Google Scholar : PubMed/NCBI
22	Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF and Carrel S: Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol. 53:21–28. 1981. View Article : Google Scholar : PubMed/NCBI
23	Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L, et al: Stem cell marker nestin and c-jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res. 13:6970–6977. 2007. View Article : Google Scholar
24	Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell. 60:585–595. 1990. View Article : Google Scholar : PubMed/NCBI
25	Roskoski R: ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 66:105–143. 2012. View Article : Google Scholar : PubMed/NCBI
26	Albert L, Karsy M, Murali R and Jhanwar-Uniyal M: Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics. 6:255–261. 2009.PubMed/NCBI
27	Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, et al: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 28:1930–1939. 2010. View Article : Google Scholar : PubMed/NCBI
28	Wang B, Gao Y, Xiao Z, Chen B, Han J, Zhang J, et al: Erk1/2 promotes proliferation and inhibits neuronal differentiation of neural stem cells. Neurosci Lett. 461:252–257. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E, et al: MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells. 29:1942–1951. 2011. View Article : Google Scholar : PubMed/NCBI
30	Gulati N, Karsy M, Albert L, Murali R and Jhanwar-Uniyal M: Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol. 35:731–740. 2009.PubMed/NCBI
31	Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 18:2316–2325. 2012. View Article : Google Scholar : PubMed/NCBI
32	Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 23:5294–5304. 2005. View Article : Google Scholar : PubMed/NCBI